2019 CYIR Finalized

49 2. Immediate nicotine reduction in cigarettes resulted in greater durable decreases in biomarkers of smoke exposure than gradual nicotine reduction. 3. Immediate reduction was associated with smoking fewer ciga- rettes per day, a greater reduction in dependence and more cigarette-free days but was also associated with greater early withdrawal symptoms, greater use of non-study cigarettes and higher drop-out rates. 4. Customized approaches to low nicotine strategy that incorpo- rate the use of NRT, varenicline, or ENDS might mitigate the adverse consequences of the immediate approach. 5. The enrollment of smokers not ready to quit is an important choice and suggest that this is an intervention that does not have to be coupled to formal quit attempts or interest in quit- ting. TARGET IDENTIFICATION FOR TOBACCO DEPENDENCE Brynildsen JK, Lee BG, Perron IJ, Jin S, Kim SF, Blendy JA. Activation of AMPK by metformin improves withdrawal signs precipitated by nicotine withdrawal. PNAS 2018. 115(16):4282. Summary Despite the fact that tobacco dependence is the number one cause of preventable death in the United States and that 70% of active smokers want to quit, the armamen- tarium of agents to treat this disorder is anemic. Given the complexity of addiction and withdrawal, the lack of new targets that can be developed solely or in combination with established agents is surprising. In this study, the team builds on previous findings in murine models establishing 1) a role for the transcription factor CREB in nicotine triggered reward responses and 2) the identification of CREB targets for the elaboration of downstream pathways. In this study, AMPK which is a multi-protein complex with subunits regulated by CREB, is examined as a mediator of nicotine withdrawal. In a murine model of nicotine dependence induced by a two-week nicotine infusion, AMPK pathway activation was triggered in the hippocampus during infu- sion but receded upon withdrawal. Nicotine withdrawal in mice is punctuated by measurable anxiety behaviors. Mice treated with two activators of AMPK, including metformin, an FDA approved AMPK activator and diabetes treatment, showed none of these behaviors upon nicotine withdrawal. Finally, the loss of AMPK expression in the hippocampus resulted in enhanced anxiety symptoms upon withdrawal. Comments 1. This study demonstrates the elegant use of informative ani- mal models, genetic profiling, gene targeting, and repurposed agents to identify novel targets for a complex behavior and may be a template for the development of new agents for nicotine dependence. 2. The development of rigorous models for nicotine dependence and withdrawal is needed to further refine the exploration of candidate agents. 3. High throughput and in vitro test systems will be critical to populating a pipeline for new agents. OTHER ARTICLES OF INTEREST Adoption of Tobacco Dependence Treatment Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med. 2018 May 1;178(5):622-631. Schuster RM, Pachas GN, Stoeckel L, Cather C, Nadal M, Mischoulon D, Schoenfeld DA, Zhang H, Ulysse C, Dodds EB, Sobolewski S, Hudziak V, Hanly A, Fava M, Evins AE. Phase IIb Trial of an α7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence. J Clin Psychopharmacol. 2018 Aug;38(4):307- 316. Preloading Investigators. Effects on abstinence of nico- tine patch treatment before quitting smoking: parallel, two arm, pragmatic randomised trial. BMJ. 2018 Jun 13;361:k2164. Melzer AC, Clothier BA, Japuntich SJ, Noorbaloochi S, Hammett P, Burgess DJ, Joseph AM, Fu SS. Comparative Effectiveness of Proactive Tobacco Treatment among Smokers with and without Chronic Lower Respiratory Disease. Ann Am Thorac Soc. 2018 Mar;15(3):341-347. Gilbody S, Peckham E, Bailey D, Arundel C, Heron P, Crosland S, Fairhurst C, Hewitt C, Li J, Parrott S, Bradshaw T, Horspool M, Hughes E, Hughes T, Ker S, Leahy M, McCloud T, Osborn D, Reilly J, Steare T, Ballantyne E, Bidwell P, Bonner S, Brennan D, Callen T, Carey A, Colbeck C, Coton D, Donaldson E, Evans K, Herlihy H, Khan W, Nyathi L, Nyamadzawo E, Oldknow H, Phiri P, Rathod S, Rea J, Romain-Hooper CB, Smith K, Stribling A, Vickers C. Smoking cessation for people with severe mental ill- ness (SCIMITAR+): a pragmatic randomised controlled trial. Lancet Psychiatry . 2019 Apr 8. Evins AE, Benowitz NL, West R, Russ C, McRae T, Lawrence D, Krishen A, St Aubin L, Maravic MC, Anthenelli RM. Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. J Clin Psychopharmacol 2019 39:108-116. New Approaches to Tobacco Dependence Treatment Halpern SD, Harhay MO, Saulsgiver K, Brophy C, Troxel AB, Volpp KG. A Pragmatic Trial of E-Cigarettes, TOBACCO DEPENDENCE

RkJQdWJsaXNoZXIy MTM1ODMw